Development of an Immune-Related Risk Signature for Predicting Prognosis in Lung Squamous Cell Carcinoma
Lung squamous cell carcinoma (LSCC) is the most common subtype of non-small cell lung cancer. Immunotherapy has become an effective treatment in recent years, while patients showed different responses to the current treatment. It is vital to identify the potential immunogenomic signatures to predict...
Main Authors: | Denggang Fu, Biyu Zhang, Lei Yang, Shaoxin Huang, Wang Xin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-08-01
|
Series: | Frontiers in Genetics |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fgene.2020.00978/full |
Similar Items
-
Identification of a DNA damage repair gene‐related signature for lung squamous cell carcinoma prognosis
by: Bin Jia, et al.
Published: (2022-04-01) -
Development and validation of a combined glycolysis and immune prognostic signature for lung squamous cell carcinoma
by: Qiang Huang, et al.
Published: (2022-09-01) -
A TP53-associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma
by: Feng Xu, et al.
Published: (2020-01-01) -
A 16-gene signature predicting prognosis of patients with oral tongue squamous cell carcinoma
by: Zeting Qiu, et al.
Published: (2017-11-01) -
Construction and validation of a seven-microRNA signature as a prognostic tool for lung squamous cell carcinoma
by: Gan Z, et al.
Published: (2019-06-01)